Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers
Currently approved anti-COVID-19 vaccines have been found to be safe and effective and almost 60% of Israeli residents are already vaccinated with BNT162b2 vaccine. This observational study was designed to evaluate the adverse events of vaccine reported by 61 healthcare workers at least 7 days after...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2022-01, Vol.40 (3), p.428-431 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 431 |
|---|---|
| container_issue | 3 |
| container_start_page | 428 |
| container_title | Vaccine |
| container_volume | 40 |
| creator | Izak, Marina Stoyanov, Evgeniy Dezuraev, Keren Shinar, Eilat |
| description | Currently approved anti-COVID-19 vaccines have been found to be safe and effective and almost 60% of Israeli residents are already vaccinated with BNT162b2 vaccine.
This observational study was designed to evaluate the adverse events of vaccine reported by 61 healthcare workers at least 7 days after the 2nd vaccination, and to investigate the correlation of adverse events and anti-SARS-CoV-2 IgG antibody levels.
The median participant's age was 51.25 years, 16 men and 45 women; 77% (44% of male and 84.5% of female participants) reported adverse events. Injection site pain, fatigue and fever were the most common symptoms, and significantly higher antibody levels (average 19,387 AU/mL) were found in participants who had fever compared to those who did not experience fever (average antibody levels of 9,977 AU/mL, p |
| doi_str_mv | 10.1016/j.vaccine.2021.11.082 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2610079517</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X21015577</els_id><sourcerecordid>2610079517</sourcerecordid><originalsourceid>FETCH-LOGICAL-e1125-2e8b7b6392d0559e9edf97e525d8f3d9188132873f0eff7af0441b84779af1853</originalsourceid><addsrcrecordid>eNo1kcFuEzEQhi0EoqHwCCAfuXjx2Ovs-oTCAiVS1UpNqbhZ3vW4cdisg71J1LfhUdkq4TSamU-_Zv6fkPfAC-Aw_7QpDrbrwoCF4AIKgILX4gWZQV1JJhTUL8mMi3nJSuC_LsibnDeccyVBvyYXstRcykrNyN8mpoS9HUMcaPR0MYyBrRZ3K9bEByboCljeYRd86JaPV9RO6za6J9rjAfs89Y5ad8CUkU6TYczUx76PxzA80tOBJ-ljGNf0y809zEUr6PbuZkGb24flVwb6zCENA12j7cd1ZxPSY0y_J9235JW3fcZ353pJfn7_dt_8YNe3V8tmcc0QQCgmsG6rdi61cFwpjRqd1xUqoVztpdNQ1yDF5I3n6H1lPS9LaOuyqrT1UCt5ST6edHcp_tljHs025A773g4Y99mIOXBeaQXVhH44o_t2i87sUtja9GT-uzoBn0_AZBEeAiaTu4BDhy4k7EbjYjDAzXOOZmPO75vnHA2AmXKU_wAOh5Bj</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2610079517</pqid></control><display><type>article</type><title>Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Izak, Marina ; Stoyanov, Evgeniy ; Dezuraev, Keren ; Shinar, Eilat</creator><creatorcontrib>Izak, Marina ; Stoyanov, Evgeniy ; Dezuraev, Keren ; Shinar, Eilat</creatorcontrib><description>Currently approved anti-COVID-19 vaccines have been found to be safe and effective and almost 60% of Israeli residents are already vaccinated with BNT162b2 vaccine.
This observational study was designed to evaluate the adverse events of vaccine reported by 61 healthcare workers at least 7 days after the 2nd vaccination, and to investigate the correlation of adverse events and anti-SARS-CoV-2 IgG antibody levels.
The median participant's age was 51.25 years, 16 men and 45 women; 77% (44% of male and 84.5% of female participants) reported adverse events. Injection site pain, fatigue and fever were the most common symptoms, and significantly higher antibody levels (average 19,387 AU/mL) were found in participants who had fever compared to those who did not experience fever (average antibody levels of 9,977 AU/mL, p < 0.001). This finding corresponds to previous observations of higher anti-SARS-CoV-2 IgG antibody levels in COVID-19 patients presented with fever.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2021.11.082</identifier><identifier>PMID: 34903375</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Anti-SARS-CoV-2 S1-specific IgG antibody levels ; BNT162 Vaccine ; COVID-19 ; COVID-19 Vaccines ; Female ; Health Personnel ; Humans ; Individuals presented with fever after vaccination had higher antibody levels ; Male ; Middle Aged ; RNA, Messenger ; SARS-CoV-2 ; Vaccination ; Vaccination with BNT162b2 mRNA COVID-19 Vaccine</subject><ispartof>Vaccine, 2022-01, Vol.40 (3), p.428-431</ispartof><rights>2021 Elsevier Ltd</rights><rights>Copyright © 2021 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X21015577$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34903375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Izak, Marina</creatorcontrib><creatorcontrib>Stoyanov, Evgeniy</creatorcontrib><creatorcontrib>Dezuraev, Keren</creatorcontrib><creatorcontrib>Shinar, Eilat</creatorcontrib><title>Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Currently approved anti-COVID-19 vaccines have been found to be safe and effective and almost 60% of Israeli residents are already vaccinated with BNT162b2 vaccine.
This observational study was designed to evaluate the adverse events of vaccine reported by 61 healthcare workers at least 7 days after the 2nd vaccination, and to investigate the correlation of adverse events and anti-SARS-CoV-2 IgG antibody levels.
The median participant's age was 51.25 years, 16 men and 45 women; 77% (44% of male and 84.5% of female participants) reported adverse events. Injection site pain, fatigue and fever were the most common symptoms, and significantly higher antibody levels (average 19,387 AU/mL) were found in participants who had fever compared to those who did not experience fever (average antibody levels of 9,977 AU/mL, p < 0.001). This finding corresponds to previous observations of higher anti-SARS-CoV-2 IgG antibody levels in COVID-19 patients presented with fever.</description><subject>Anti-SARS-CoV-2 S1-specific IgG antibody levels</subject><subject>BNT162 Vaccine</subject><subject>COVID-19</subject><subject>COVID-19 Vaccines</subject><subject>Female</subject><subject>Health Personnel</subject><subject>Humans</subject><subject>Individuals presented with fever after vaccination had higher antibody levels</subject><subject>Male</subject><subject>Middle Aged</subject><subject>RNA, Messenger</subject><subject>SARS-CoV-2</subject><subject>Vaccination</subject><subject>Vaccination with BNT162b2 mRNA COVID-19 Vaccine</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kcFuEzEQhi0EoqHwCCAfuXjx2Ovs-oTCAiVS1UpNqbhZ3vW4cdisg71J1LfhUdkq4TSamU-_Zv6fkPfAC-Aw_7QpDrbrwoCF4AIKgILX4gWZQV1JJhTUL8mMi3nJSuC_LsibnDeccyVBvyYXstRcykrNyN8mpoS9HUMcaPR0MYyBrRZ3K9bEByboCljeYRd86JaPV9RO6za6J9rjAfs89Y5ad8CUkU6TYczUx76PxzA80tOBJ-ljGNf0y809zEUr6PbuZkGb24flVwb6zCENA12j7cd1ZxPSY0y_J9235JW3fcZ353pJfn7_dt_8YNe3V8tmcc0QQCgmsG6rdi61cFwpjRqd1xUqoVztpdNQ1yDF5I3n6H1lPS9LaOuyqrT1UCt5ST6edHcp_tljHs025A773g4Y99mIOXBeaQXVhH44o_t2i87sUtja9GT-uzoBn0_AZBEeAiaTu4BDhy4k7EbjYjDAzXOOZmPO75vnHA2AmXKU_wAOh5Bj</recordid><startdate>20220124</startdate><enddate>20220124</enddate><creator>Izak, Marina</creator><creator>Stoyanov, Evgeniy</creator><creator>Dezuraev, Keren</creator><creator>Shinar, Eilat</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20220124</creationdate><title>Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers</title><author>Izak, Marina ; Stoyanov, Evgeniy ; Dezuraev, Keren ; Shinar, Eilat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e1125-2e8b7b6392d0559e9edf97e525d8f3d9188132873f0eff7af0441b84779af1853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Anti-SARS-CoV-2 S1-specific IgG antibody levels</topic><topic>BNT162 Vaccine</topic><topic>COVID-19</topic><topic>COVID-19 Vaccines</topic><topic>Female</topic><topic>Health Personnel</topic><topic>Humans</topic><topic>Individuals presented with fever after vaccination had higher antibody levels</topic><topic>Male</topic><topic>Middle Aged</topic><topic>RNA, Messenger</topic><topic>SARS-CoV-2</topic><topic>Vaccination</topic><topic>Vaccination with BNT162b2 mRNA COVID-19 Vaccine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Izak, Marina</creatorcontrib><creatorcontrib>Stoyanov, Evgeniy</creatorcontrib><creatorcontrib>Dezuraev, Keren</creatorcontrib><creatorcontrib>Shinar, Eilat</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Izak, Marina</au><au>Stoyanov, Evgeniy</au><au>Dezuraev, Keren</au><au>Shinar, Eilat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2022-01-24</date><risdate>2022</risdate><volume>40</volume><issue>3</issue><spage>428</spage><epage>431</epage><pages>428-431</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Currently approved anti-COVID-19 vaccines have been found to be safe and effective and almost 60% of Israeli residents are already vaccinated with BNT162b2 vaccine.
This observational study was designed to evaluate the adverse events of vaccine reported by 61 healthcare workers at least 7 days after the 2nd vaccination, and to investigate the correlation of adverse events and anti-SARS-CoV-2 IgG antibody levels.
The median participant's age was 51.25 years, 16 men and 45 women; 77% (44% of male and 84.5% of female participants) reported adverse events. Injection site pain, fatigue and fever were the most common symptoms, and significantly higher antibody levels (average 19,387 AU/mL) were found in participants who had fever compared to those who did not experience fever (average antibody levels of 9,977 AU/mL, p < 0.001). This finding corresponds to previous observations of higher anti-SARS-CoV-2 IgG antibody levels in COVID-19 patients presented with fever.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>34903375</pmid><doi>10.1016/j.vaccine.2021.11.082</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2022-01, Vol.40 (3), p.428-431 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2610079517 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anti-SARS-CoV-2 S1-specific IgG antibody levels BNT162 Vaccine COVID-19 COVID-19 Vaccines Female Health Personnel Humans Individuals presented with fever after vaccination had higher antibody levels Male Middle Aged RNA, Messenger SARS-CoV-2 Vaccination Vaccination with BNT162b2 mRNA COVID-19 Vaccine |
| title | Correlation of Anti-SARS-CoV-2 S1-specificIgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A15%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20of%20Anti-SARS-CoV-2%20S1-specificIgG%20antibody%20levels%20and%20adverse%20events%20following%20vaccination%20with%20BNT162b2%20mRNA%20COVID-19%20vaccine%20in%20healthcare%20workers&rft.jtitle=Vaccine&rft.au=Izak,%20Marina&rft.date=2022-01-24&rft.volume=40&rft.issue=3&rft.spage=428&rft.epage=431&rft.pages=428-431&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2021.11.082&rft_dat=%3Cproquest_pubme%3E2610079517%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2610079517&rft_id=info:pmid/34903375&rft_els_id=S0264410X21015577&rfr_iscdi=true |